Letvex

Letvex

letrozole

Manufacturer:

Vexxa Lifesciences

Distributor:

VE Pharma
Concise Prescribing Info
Contents
Letrozole
Indications/Uses
Extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 yr of adjuvant tamoxifen therapy. 1st-line treatment of postmenopausal women w/ hormone receptor +ve or unknown locally advanced, or metastatic breast cancer. Advanced breast cancer in postmenopausal women w/ disease progression following anti-estrogen therapy.
Dosage/Direction for Use
Adult & elderly 2.5 mg once daily. In adjuvant setting & standard adjuvant tamoxifen therapy should continue for 5 yr or until tumour relapse occurs.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Pre-op use if the receptor status is -ve or unknown. Severe hepatic impairment (Child-Pugh grade C). Premenopausal women. Pregnancy & lactation.
Special Precautions
Assess & initiate treatment for bone mineral density of women w/ or at risk of osteoporosis. Patients w/ CrCl <10 mL/min. Not for use in men w/ breast cancer. Hepatic &/or renal impairment. Not recommended for childn.
Adverse Reactions
Hot flashes, arthralgia; flushing, asthenia, edema, headache, dizziness, hypercholesterolemia, increased sweating, bone pain & musculoskeletal.
Drug Interactions
Reduced plasma levels w/ tamoxifen (20 mg).
ATC Classification
L02BG04 - letrozole ; Belongs to the class of enzyme inhibitors. Used in treatment of neoplastic diseases.
Presentation/Packing
Form
Letvex FC tab 2.5 mg
Packing/Price
30's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in